Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esther Drill

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Plos One|October 3, 2012
Can genetic pleiotropy replicate common clinical constellations of cardiovascular disease and risk?Omri Gottesman, Esther Drill, Vaneet Lotay, et al.
Surgical Oncology|April 15, 2021
Postoperative extremity compartment syndrome in a cancer center: Incidence and risk factorsMax Vaynrub, Omer Or, Esther Drill, et al.
Breast Cancer Research and Treatment|February 6, 2019
Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fractionYasin Hussain, Esther Drill, Chau T Dang, et al.
Journal of Pediatric Hematology/Oncology|February 25, 2017
Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric PatientsDazhi Liu, Brian Seyboth, Sherry Mathew, et al.
Leukemia Research|March 16, 2018
Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemiaAmanda N Seddon, Joshua Chaim, Oguz Akin, et al.
Oncology (Williston Park, N.Y.)|January 28, 2022
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabEsther Drill, Annie Qiu, Sheila Shapouri, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 20, 2021
IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern EraMichael J Buege, Phuong H Dao, Esther Drill, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2014
FGF5 is a crucial regulator of hair length in humansClaire A Higgins, Lynn Petukhova, Sivan Harel, et al.
European Journal of Haematology|March 27, 2023
Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposureMichael J Buege, Esther Drill, Steven M Horwitz, et al.
The American Journal of Surgical Pathology|July 19, 2017
Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands: A Clinicopathologic Study With Correlation Between MYB Fusion and Protein ExpressionBin Xu, Esther Drill, Allen Ho, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Plos One|October 3, 2012
Can genetic pleiotropy replicate common clinical constellations of cardiovascular disease and risk?Omri Gottesman, Esther Drill, Vaneet Lotay, et al.
Surgical Oncology|April 15, 2021
Postoperative extremity compartment syndrome in a cancer center: Incidence and risk factorsMax Vaynrub, Omer Or, Esther Drill, et al.
Breast Cancer Research and Treatment|February 6, 2019
Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fractionYasin Hussain, Esther Drill, Chau T Dang, et al.
Journal of Pediatric Hematology/Oncology|February 25, 2017
Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric PatientsDazhi Liu, Brian Seyboth, Sherry Mathew, et al.
Leukemia Research|March 16, 2018
Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemiaAmanda N Seddon, Joshua Chaim, Oguz Akin, et al.
Oncology (Williston Park, N.Y.)|January 28, 2022
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabEsther Drill, Annie Qiu, Sheila Shapouri, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 20, 2021
IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern EraMichael J Buege, Phuong H Dao, Esther Drill, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 4, 2014
FGF5 is a crucial regulator of hair length in humansClaire A Higgins, Lynn Petukhova, Sivan Harel, et al.
European Journal of Haematology|March 27, 2023
Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposureMichael J Buege, Esther Drill, Steven M Horwitz, et al.
The American Journal of Surgical Pathology|July 19, 2017
Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands: A Clinicopathologic Study With Correlation Between MYB Fusion and Protein ExpressionBin Xu, Esther Drill, Allen Ho, et al.
Pageof 5